BCYC

2.9004.92%
HH

Herve Hoppenot

Independent Director

Mr. Hervé Hoppenot serves as Director at Pierre Fabre SA since January 15, 2024 and is its Chairman of the Board since May 21, 2026. He is Chairman of the Board of Maze Therapeutics, Inc. from October 6, 2025 having joined in October 2025. Mr. Hoppenot served as Director of Incyte Corporation until December 12, 2025 and had been its Advisor to CEO since June 26, 2025 until December 12, 2025. He serves as Independent Director at Bicycle Therapeutics plc since September 8, 2025. He had been the Chairman of the Board at Incyte Corporation since May 2015 until June 26, 2025 and served as its Chief Executive Officer until June 26, 2025 and was President since January 13, 2014 until June 26, 2025. Mr. Hoppenot served as the Chief Commercial Officer and Head of Global Product Strategy & Scientific Development at Incyte Corporation, where he oversaw medical affairs, global brand leadership, business development and licensing, health economics & pricing, early phase commercial development, strategic capabilities and global sales excellence for Oncology. He joined Novartis in 2003 and served as its Senior Vice President and Head of Global Marketing from 2003 to September 2006. He was responsible for translational medicine, development, approval and commercialization, which included 11 billion in global sales, the largest oncology pipeline in the industry and 8,000 employees in 50 countries. He has more than twenty-five years of international experience. He started his career in France with Rhone Poulenc, later known as Aventis, where he served in several senior roles of increasing responsibility, including Vice President of Oncology and Head of the U.S. Oncology business unit. From 2003 to September 2006 as Senior Vice President, Head of Global Marketing of Novartis Oncology. Mr. Hoppenot has been a Director of Incyte Corporation since January 13, 2014. Mr. Hoppenot joined the Incyte Corporation on January 13, 2014. Mr. Hoppenot served as the President of Novartis Oncology from January 2010 to January 2014. Prior to that, Mr. Hoppenot served in other executive positions at Novartis Pharmaceuticals Corporation, serving from September 2006 to January 2010 as Executive Vice President, Chief Commercial Officer of Novartis Oncology and Head of Global Product Strategy & Scientific Development of Novartis Pharmaceuticals Corporation. Prior to joining Novartis, Mr. Hoppenot served in various increasingly senior roles at Aventis S.A. (formerly Rhône-Poulenc S.A.), a pharmaceutical company, including as Vice President Oncology US of Aventis Pharmaceuticals, Inc. from 2000 to 2003 and Vice President US Oncology Operations of Rhone-Poulenc Rorer Pharmaceuticals, Inc. from 1998 to 2000. Mr. Hoppenot is also a director of Cellectis S.A. He holds a Diploma from ESSEC International Business School.

Positions